#Ozempic #GLP1 #Semaglutide #AlcoholUseDisorder #WeightLoss
People on Ozempic and Wegovy are reporting a side effect that isn't on the label: they're losing interest in alcohol. Is it real, or just nausea? As an internal medicine and obesity medicine physician, I work this up like an unexplained finding in a hospital patient. We'll look at the patient reports and real-world data, consider every possible explanation, read the newest trials (including the 2026 Lancet trial), and finish with a practical plan.
In this video you'll learn:
Why GLP-1 drugs may turn down cravings, and what "food noise" really is
What the Lancet, JAMA Psychiatry and earlier trials actually found
Why the first human trial failed, and how it shaped the one that worked
What we still don't know before this becomes a standard treatment
5 safety rules if you drink while on a GLP-1
TIMESTAMPS
0:00 – A strange answer on the admission form
1:44 – What patients are reporting (and what the data shows)
3:20 – Why this matters: the alcohol treatment gap
4:43 – Three possible explanations
7:43 – How GLP-1s act on the brain: the two buttons
10:36 – Protecting your muscle on a GLP-1
11:17 – The 2026 Lancet trial
12:43 – The lab trial: what changed and what didn't
13:53 – The trial that failed, and what it taught us
15:33 – Animal research foundations
16:28 – Would I prescribe it for alcohol today?
18:46 – 5 rules before your next drink on a GLP-1
20:30 – Treatments that already work
21:46 – Final thoughts and resources
🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com
📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter
REFERENCES
Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. Lancet. 2026;407(10540):1687–1698. https://doi.org/10.1016/S0140-6736(26)00305-3
Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405.
Klausen MK, et al. Exenatide once weekly for alcohol use disorder. JCI Insight. 2022;7(19):e159863. https://insight.jci.org/articles/view/159863
Lähteenvuo M, et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82(1):94–98.
Wang W, Volkow ND, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder. Nat Commun. 2024;15:4548. https://doi.org/10.1038/s41467-024-48780-6
Quddos F, et al. Physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity. Sci Rep. 2025. https://doi.org/10.1038/s41598-025-17927-w
Suchankova P, et al. The GLP-1 receptor as a potential treatment target in alcohol use disorder. Transl Psychiatry. 2015;5:e583. https://www.nature.com/articles/tp201568
Thomsen M, et al. GLP-1 analogs and alcohol intake in vervet monkeys. Psychopharmacology. 2019;236:603–611.
Aranäs C, et al. Semaglutide reduces alcohol intake and relapse-like drinking in rats. eBioMedicine. 2023;93:104642.
Leggio L, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29:2993–2995.
Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016;71(8):670–679.
Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:363–371.
Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
Jonas DE, et al. Pharmacotherapy for adults with alcohol use disorders. JAMA. 2014;311(18):1889–1900.
Han B, et al. Use of medications for alcohol use disorder in the US. JAMA Psychiatry. 2021;78(8):922–924.
World Health Organization. Global status report on alcohol and health. 2024.
U.S. Surgeon General. Alcohol and Cancer Risk Advisory. 2025.
⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
